Dyne Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Dyne Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-37.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 68% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-80.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 80% of Healthcare companies in United States.
Cash Cushion Ratio
+32%Cash, after subtracting all debt, equals 32% of its market value (net cash).
Higher than 69% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Dyne Therapeutics, Inc. made a loss over the last year. Dyne Therapeutics, Inc. owes $0.29 for every $1 it owns. Dyne Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossDyne Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
4.19The share price is 4.19 times Dyne Therapeutics, Inc.'s book value per share, higher than 67% of Healthcare companies in United States.
Market cap
$2.9 BThe total market value of all of Dyne Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 80% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$702 MWhat Dyne Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.76Net worth divided by the number of shares. The share price of $15.77 is 4.2 times this, which is the P/B above.
Return on equity (ROE)
-81.6%Dyne Therapeutics, Inc. lost 81.6% of its shareholders' money over the last year, lower than 66% of Healthcare companies in United States.
Owes vs Owns
0.29×Dyne Therapeutics, Inc. owes $0.29 for every $1 it owns (low), lower than 60% of Healthcare companies in United States.
Dividend yield
NoneDyne Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossDyne Therapeutics, Inc. made a loss in each of the last two years.
Interest cover
Not coveredDyne Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashDyne Therapeutics, Inc. held $941 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Dyne Therapeutics, Inc.: $2.9 B ÷ $702 M (30 Jun 2026) = 4.2.
What is Dyne Therapeutics, Inc.'s return on equity?
Dyne Therapeutics, Inc. lost 81.6% of its shareholders' money over the last year, lower than 66% of Healthcare companies in United States.
How much does Dyne Therapeutics, Inc. owe compared with what it owns?
Dyne Therapeutics, Inc. owes $0.29 for every $1 it owns (low), lower than 60% of Healthcare companies in United States.
Does Dyne Therapeutics, Inc. pay a dividend?
No. Dyne Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.